SignalPoint Asset Management LLC boosted its position in shares of Gilead Sciences Inc. (NASDAQ:GILD) by 7.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,212 shares of the biopharmaceutical company’s stock after buying an additional 302 shares during the period. SignalPoint Asset Management LLC’s holdings in Gilead Sciences were worth $351,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in GILD. BNP Paribas Arbitrage SA boosted its stake in Gilead Sciences by 0.4% in the second quarter. BNP Paribas Arbitrage SA now owns 2,170,640 shares of the biopharmaceutical company’s stock worth $181,075,000 after buying an additional 8,430 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its stake in Gilead Sciences by 17.5% in the first quarter. Adage Capital Partners GP L.L.C. now owns 1,739,537 shares of the biopharmaceutical company’s stock worth $159,794,000 after buying an additional 258,807 shares in the last quarter. Geode Capital Management LLC boosted its stake in Gilead Sciences by 1.3% in the first quarter. Geode Capital Management LLC now owns 12,410,846 shares of the biopharmaceutical company’s stock worth $1,137,969,000 after buying an additional 161,505 shares in the last quarter. Temasek Holdings Private Ltd boosted its stake in Gilead Sciences by 8.1% in the first quarter. Temasek Holdings Private Ltd now owns 13,830,516 shares of the biopharmaceutical company’s stock worth $1,270,471,000 after buying an additional 1,035,592 shares in the last quarter. Finally, Omega Advisors Inc. bought a new stake in Gilead Sciences during the first quarter worth approximately $47,491,000. 78.00% of the stock is owned by institutional investors.
Shares of Gilead Sciences Inc. (NASDAQ:GILD) traded up 1.06% during mid-day trading on Tuesday, reaching $73.41. 6,353,498 shares of the company were exchanged. The firm has a market capitalization of $96.88 billion, a price-to-earnings ratio of 6.44 and a beta of 1.10. Gilead Sciences Inc. has a 12 month low of $72.21 and a 12 month high of $111.11. The company’s 50-day moving average is $77.59 and its 200 day moving average is $84.05.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share for the quarter, beating analysts’ consensus estimates of $3.02 by $0.06. The firm had revenue of $7.78 billion for the quarter, compared to analysts’ expectations of $7.80 billion. Gilead Sciences had a net margin of 50.50% and a return on equity of 106.75%. Gilead Sciences’s revenue was down 5.7% compared to the same quarter last year. During the same period in the previous year, the company posted $3.15 earnings per share. Analysts predict that Gilead Sciences Inc. will post $11.76 EPS for the current year.
The firm also recently declared a quarterly dividend, which was paid on Thursday, September 29th. Shareholders of record on Friday, September 16th were given a dividend of $0.47 per share. The ex-dividend date was Wednesday, September 14th. This represents a $1.88 dividend on an annualized basis and a yield of 2.56%. Gilead Sciences’s dividend payout ratio (DPR) is 16.56%.
A number of analysts have recently commented on GILD shares. Royal Bank Of Canada boosted their target price on shares of Gilead Sciences from $95.00 to $105.00 and gave the stock an “outperform” rating in a research note on Monday, October 3rd. Jefferies Group cut their target price on shares of Gilead Sciences from $93.00 to $91.00 and set a “hold” rating for the company in a research note on Wednesday, August 31st. Zacks Investment Research raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Monday, September 26th. Piper Jaffray Cos. reissued an “overweight” rating and set a $108.00 target price on shares of Gilead Sciences in a research note on Wednesday, August 31st. Finally, Leerink Swann set a $112.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Thursday, September 22nd. Ten research analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $102.78.
In other Gilead Sciences news, insider John C. Martin sold 100,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $80.50, for a total transaction of $8,050,000.00. Following the transaction, the insider now directly owns 4,119,727 shares of the company’s stock, valued at $331,638,023.50. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider John F. Milligan sold 70,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, September 6th. The shares were sold at an average price of $77.74, for a total transaction of $5,441,800.00. Following the transaction, the insider now directly owns 1,128,963 shares in the company, valued at $87,765,583.62. The disclosure for this sale can be found here. Company insiders own 1.40% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.